Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2009-05-14
2010-06-29
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S617000
Reexamination Certificate
active
07745662
ABSTRACT:
Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada
patent: 5112946 (1992-05-01), Maione
patent: 5192744 (1993-03-01), Bouck
patent: 5202352 (1993-04-01), Okada
patent: 02/100295 (2002-12-01), None
Gong et al., Creating nanocavities of tunable sizes: Hollow helices, 2002, PNAS 99(18):11583-11588.
Folkman, et al.,; Inhibition of Angiogenesis; Cancer Biology; vol. 3, 1992; pp. 89-96.
Moses, et al.,; Identification of an Inhibitor of Neovascularization From Cartilage; Science, vol. 248, pp. 1408-1410.
Blood, et al.; Tumor Interactions With the Vasculature; Angiogenesis and Tumor Metastasis; Biochimica et Biophysica Acta; 1032 (1990) pp. 89-118; Elsevier Science Publishers B.V. (Biomedical Division).
Cogan, et al., J. Med. Chem., 2003, 46, 5258-5270.
Huff, J. Med. Chem., 1991;vol. 34, No. 8:2305-2314.
National Eye Institute, Congressional Justification of FY 2004,]http://www.nei.nih.gov
ews/congressjust/cj2004.asp.
National Cancer Institute, Bevacizumab Combined with Chemotherapy Prolongs Survival for Some Patients with Advanced Lung Cancer, http://www.cancer.gov
ewscenter/pressreleasea/AvastinLung.
National Cancer Institute, Bevacizumab Combined with Chemotherapy Improves Progression-Free Survival for Patients with Advanced Breast Cancer, http://www.cancer.gov
ewscenter/pressreleases/AvastinBreast.
National Cancer Institute, Thalidomide Shows Activity Against.AIDS-Related Kaposi's Sarcoma, http://www.cancer.gov
ewscenter/thalidomideks.
National Cancer Institute, Bevacizumab (Avastin) Improves Survival in Metastatic Colorectal Cancer, cancer.gov/clini{altrials/results/bevacizumab-and-colorectal-cancer0601.
National Cancer Institute, Adding Bevacizumab (Avastin) Improves Outcomes in Advanced Colorectal Caricer. http://www.cancer.gov/clinicaltrials/results/bevacizumab-and-coloreGtaf0505.
National Cancer Institute, Moleculary Targeted Drug Slows Tumor Growth in Patients with Metastatic Kidney Cancer, http://www.cancer.gov
ewscenter/Yang.
National Cancer Institute, Bevacizumab Combined with OxalipiatJn-Based Chemotherapy Prolongs Survival for Previously Treated Patients with Advanced Colorectal Cancer http://www.cancer.gov
ewscenter/pressreleases/BevacizumabOxaliplatin.
National Cancer Institute, Bevacizumab (Avastin) for Treatment of Solid Tumors: Questions and Answers, http://www.cancer.gov/cancertopics/factsheet/AvastinFactSheet.
Erwin A. Kruger et al, TNP-470: an angiongenesis inhibitor in clinical development for cancer, Expert Opinion on Investigational Drugs, 2000, pp. 1383-1396,9(6), Ashley Publications Ltd.
Amir Abdollahi et al., Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and antitumor Effects, Cancer Research 63, Dec. 15, 2003, pp. 8890-2298.
Evangelos S. Gragoudas et al. Pegaptanibfor Neovascular Age-Related Macular Degneration, The New England Journal of Medicine, Dec. 30, 2004, pp. 2805-2816, 351; 27.
Xinkang Wang et al., Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembokic Stroke in Rats, Stroke, Feb. 2003, pp. 468-474.
Kazimierz Ostrowski et al., Inhibition of Angiogenesis in tie Treatment of Tumors, Archivum Immuhologiae et therapiac Experiments, 2001, pp. 27-31,49.
W. R. Gould et al., Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors, Current Pharmaceutical Design, 2003, pp. 2337-2347.9. Bentham Science Publishers Ltd.
Hiroakimatsuno etal., Treatment with Angiogenesis Inhibitor Endostatin: A Novel Therapy in Rheumatoid Arthritis, The Journal of Rheumatology, 2002, pp. 890-895, 29:5.
Marian Ziche et al, Development of New Drugs in Angiogenesis. Current Drug Targets. 2004. pp. 485-493, 5, Bentham Science Publishers Ltd.
Afshin Shafieeetal., Inhibition of Retinal angiogenesis by Peptides Derived from Thrombospondin-i:, Investigative Ophthalmology & Visual Science, Jul. 2000, pp. 2378-2388, vol. 41, No. 8.
Gary W. McCollum et al., Herbimycin A inhibits angiogepic activity in endothelial cells and reduces neovascuiarization in a rat model of retinopathy of prematurity! Experimental Eye Research 78, 2007, pp. 987-995.
Joel R. Huff, HIV Protease: A Novel Chemotherapeutic Target for AIDS, Journal of Medicinal Chemistry, Aug. 1991, pp. 2305-2314, vol. 34. No. 6.
M. Hess et al., Terminology of Polymers Containing Ionizable or Ionic Groups and of Polymers Containing Ions, International Union of Pure and Applied Chemistry, Dec. 23, 2004, pp. 1-12.
Kumar Shailendra
Pepper Hamilton LLP
Polymedix, Inc.
LandOfFree
Polycationic compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polycationic compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polycationic compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175346